相关实验视频
Updated: May 14, 2025

08:07
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
Published on: April 12, 2019
7.1K
miR-486-3p通过准SPRED1-MAPK/ERK路径来抑制骨髓瘤的扩散和迁移
Yu Zhang1, Yi Zhou2, Sen Zhang2
1Department of Orthopaedics, The First People's Hospital of Chengdu, Chengdu, Sichuan Province, China.
Biochemical genetics
|May 13, 2025
概括
微RNA-486-3p (miR-486-3p) 在骨髓瘤 (OS) 中降低调节,并抑制瘤生长. 恢复miR-486-3p水平通过向SPRED1和禁用ERK1/2通路来抑制OS进展,提供潜在的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 基因规则 基因规则
背景情况:
- 骨髓瘤 (OS) 是一种主要的骨癌,其特征是不受控制的树皮细胞增殖.
- 线原激活蛋白激酶 (MAPK) 途径,特别是ERK1/2,对于OS瘤生长和转移至关重要.
- 基于微RNA (miRNA) 的诊断和治疗方法为OS治疗提供了新的途径.
研究的目的:
- 研究 miR-486-3p 在骨髓瘤内ERK1/2通路中的调节作用.
- 在OS中分析miR-486-3p及其目标基因SPRED1的表达模式.
- 评估在OS中调节miR-486-3p的治疗潜力.
主要方法:
- 在GEO数据集 (GSE65071) 和临床OS样本中分析miR-486-3p表达.
- 使用OS细胞的体外研究和使用瘤携带小鼠的体内研究来评估miR-486-3p功能.
- 生物信息分析和功能测定 (功能损失和增益) 以确定和验证miR-486-3p目标和途径.
主要成果:
- 在OS组织中,miR-486-3p的表达下调,与先进的临床阶段相关.
- 过度表达miR-486-3p显著抑制了OS细胞的增殖,迁移和入侵.
- miR-486-3p直接准SPRED1,导致ERK1/2通路的失活,并调节上皮层到介质细胞转换 (EMT) 标记物.
结论:
- 通过对SPRED1进行上调和激活ERK1/2通路,对miR-486-3p的下调有助于OS的进展.
- miR-486-3p在骨髓瘤中充当瘤抑制剂.
- 针对miR-486-3p/SPRED1/ERK1/2轴对新型骨髓瘤治疗具有前景.
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
3.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.3K
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
mTOR Signaling and Cancer Progression
3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.6K
MicroRNAs
2.9K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
2.9K
The JAK-STAT Signaling Pathway
8.4K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.4K

